These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 26190239)

  • 21. High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi.
    Ichii-Nakato N; Takata M; Takayanagi S; Takashima S; Lin J; Murata H; Fujimoto A; Hatta N; Saida T
    J Invest Dermatol; 2006 Sep; 126(9):2111-8. PubMed ID: 16691193
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential gene expression in melanocytic nevi with the V600E BRAF mutation.
    Bloethner S; Snellman E; Bermejo JL; Hiripi E; Gast A; Thirumaran RK; Wellenreuther R; Hemminki K; Kumar R
    Genes Chromosomes Cancer; 2007 Nov; 46(11):1019-27. PubMed ID: 17696195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The T1796A mutation of the BRAF gene is absent in Spitz nevi.
    Palmedo G; Hantschke M; Rütten A; Mentzel T; Hügel H; Flaig MJ; Yazdi AS; Sander CA; Kutzner H
    J Cutan Pathol; 2004 Mar; 31(3):266-70. PubMed ID: 14984580
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clonal BRAF mutations in melanocytic nevi and initiating role of BRAF in melanocytic neoplasia.
    Yeh I; von Deimling A; Bastian BC
    J Natl Cancer Inst; 2013 Jun; 105(12):917-9. PubMed ID: 23690527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evolution of melanocytic nevi under vemurafenib, followed by combination therapy with dabrafenib and trametinib for metastatic melanoma.
    Giurcaneanu C; Nitipir C; Popa LG; Forsea AM; Popescu I; Bumbacea RS
    Acta Dermatovenerol Croat; 2015; 23(2):114-21. PubMed ID: 26228819
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proliferative nodules arising within congenital melanocytic nevi: a histologic, immunohistochemical, and molecular analyses of 43 cases.
    Phadke PA; Rakheja D; Le LP; Selim MA; Kapur P; Davis A; Mihm MC; Hoang MP
    Am J Surg Pathol; 2011 May; 35(5):656-69. PubMed ID: 21436676
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis.
    Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M
    Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations.
    Bauer J; Curtin JA; Pinkel D; Bastian BC
    J Invest Dermatol; 2007 Jan; 127(1):179-82. PubMed ID: 16888631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.
    Tsavachidou D; Coleman ML; Athanasiadis G; Li S; Licht JD; Olson MF; Weber BL
    Cancer Res; 2004 Aug; 64(16):5556-9. PubMed ID: 15313890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. B-RAF and melanocytic neoplasia.
    Gill M; Celebi JT
    J Am Acad Dermatol; 2005 Jul; 53(1):108-14. PubMed ID: 15965430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In melanocytic lesions the fraction of BRAF V600E alleles is associated with sun exposure but unrelated to ERK phosphorylation.
    Venesio T; Chiorino G; Balsamo A; Zaccagna A; Petti C; Scatolini M; Pisacane A; Sarotto I; Picciotto F; Risio M
    Mod Pathol; 2008 Jun; 21(6):716-26. PubMed ID: 18408659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distribution of BRAF T1799A(V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis.
    Wu J; Rosenbaum E; Begum S; Westra WH
    Am J Dermatopathol; 2007 Dec; 29(6):534-7. PubMed ID: 18032947
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oncogenic BRAF-positive dysplastic nevi and the tumor suppressor IGFBP7--challenging the concept of dysplastic nevi as precursor lesions?
    Decarlo K; Yang S; Emley A; Wajapeyee N; Green M; Mahalingam M
    Hum Pathol; 2010 Jun; 41(6):886-94. PubMed ID: 20233623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncogenic BRAF and the tumor suppressor IGFBP7 in the genesis of atypical spitzoid nevomelanocytic proliferations.
    Emley A; Yang S; Wajapeyee N; Green MR; Mahalingam M
    J Cutan Pathol; 2010 Mar; 37(3):344-9. PubMed ID: 19788444
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mosaic BRAF Fusions Are a Recurrent Cause of Congenital Melanocytic Nevi Targetable by MAPK Pathway Inhibition.
    Martin SB; Polubothu S; Bruzos AL; Kelly G; Horswell S; Sauvadet A; Bryant D; Zecchin D; Riachi M; Michailidis F; Sadri A; Muwanga-Nanyonjo N; Lopez-Balboa P; Knöpfel N; Bulstrode N; Pittman A; Yeh I; Kinsler VA
    J Invest Dermatol; 2024 Mar; 144(3):593-600.e7. PubMed ID: 37716647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular Genomic Profiling of Melanocytic Nevi.
    Colebatch AJ; Ferguson P; Newell F; Kazakoff SH; Witkowski T; Dobrovic A; Johansson PA; Saw RPM; Stretch JR; McArthur GA; Long GV; Thompson JF; Pearson JV; Mann GJ; Hayward NK; Waddell N; Scolyer RA; Wilmott JS
    J Invest Dermatol; 2019 Aug; 139(8):1762-1768. PubMed ID: 30772300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Melanocytic nevi and melanoma: unraveling a complex relationship.
    Damsky WE; Bosenberg M
    Oncogene; 2017 Oct; 36(42):5771-5792. PubMed ID: 28604751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The association of BRAF V600E gene mutation with proliferative activity and histopathological characteristics of congenital melanocytic nevi in children.
    Chen J; Zhang G; Liu X; Tu P
    An Bras Dermatol; 2023; 98(4):498-505. PubMed ID: 37156689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction.
    Turner DJ; Zirvi MA; Barany F; Elenitsas R; Seykora J
    J Cutan Pathol; 2005 May; 32(5):334-9. PubMed ID: 15811117
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activating mutations in the RAS/mitogen-activated protein kinase signaling pathway in sporadic trichoblastoma and syringocystadenoma papilliferum.
    Shen AS; Peterhof E; Kind P; Rütten A; Zelger B; Landthaler M; Berneburg M; Hafner C; Groesser L
    Hum Pathol; 2015 Feb; 46(2):272-6. PubMed ID: 25532942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.